The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Research Question:
Does the drug Inebilizumab improve disability in patients with a particular type of
encephalitis, called anti-N-methyl-D-aspartate receptor encephalitis?
Basic Study Information
Purpose:
Anti-N-methyl-D-aspartate receptor encephalitis is a life-threatening autoimmune disorder
for which there are no approved therapies. This study will determine if the drug,
Inebilizumab, will improve the disability of patients who have anti-N-methyl-D-aspartate
receptor encephalitis. You will be randomized to receive either standard care for
this disease, Inelbilizumab, or a placebo. You may be eligible to join if you are
18 years of age or older, have a diagnosis of anti-N-methyl-D-aspartate receptor encephalitis,
and have had a recent change in your mental status.
Location: University of Rochester
Study Web URL:
Study Reference #: STUDY00006222
Lead Researcher (Principal Investigator)
Lead Researcher:
Andrew Goodman
Study Contact Information
Study Coordinator: Christine Anne
Phone: (585) 276-3037
Email: Christine_annis@urmc.rochester.edu
Additional Study Details
Learn More About These Conditions
Trial Not Found
The study you are looking for is not active at this time.
Return to Search